MedPath

Astellas Pharma Global Development, Inc.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

A Study of ASP1570 Alone or in Combination with Pembrolizumab or Standard Therapies in Adults with Solid Tumors

Phase 1/2
Recruiting
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2024-06-17
Last Posted Date
2025-03-28
Lead Sponsor
Astellas Pharma Global Development Inc.
Target Recruit Count
98
Registration Number
2023-505084-37-00
Locations
🇪🇸

Institut Catala D'oncologia, L'hospitalet De Llobregat, Spain

🇪🇸

Hospital General Universitario Gregorio Maranon, Madrid, Spain

🇪🇸

Complexo Hospitalario Universitario De Santiago, Santiago De Compostela, Spain

and more 11 locations

A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder

Phase 2
Withdrawn
Conditions
Opioid Use Disorder
Interventions
First Posted Date
2021-09-30
Last Posted Date
2024-11-06
Lead Sponsor
Astellas Pharma Global Development, Inc.
Registration Number
NCT05062577

A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause

Phase 3
Completed
Conditions
Vasomotor Symptoms
Interventions
Drug: placebo
First Posted Date
2021-09-05
Last Posted Date
2024-10-26
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
453
Registration Number
NCT05033886
Locations
🇧🇪

Site BE32005, Tienen, Vlaams Brabant, Belgium

🇨🇦

Site CA15008, Brampton, Ontario, Canada

🇨🇦

Site CA15010, London, Ontario, Canada

and more 66 locations

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1
Recruiting
Conditions
Urinary Bladder Neoplasms
NMIBC
Carcinoma Transitional Cell
Non-muscle Invasive Bladder Cancer
Carcinoma in Situ
Interventions
Drug: Enfortumab vedotin
First Posted Date
2021-08-20
Last Posted Date
2025-03-26
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
58
Registration Number
NCT05014139
Locations
🇺🇸

Stanford Health Care, Stanford, California, United States

🇺🇸

Oregon Health and Science University, Portland, Oregon, United States

🇺🇸

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 29 locations

A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Phase 1
Completed
Conditions
Hepatic Impairment
Healthy Volunteers
Interventions
First Posted Date
2021-06-29
Last Posted Date
2024-10-21
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
25
Registration Number
NCT04942964
Locations
🇺🇸

Advanced Pharma CR, LLC, Miami, Florida, United States

🇺🇸

Orlando Clinical Research Center, Inc, Orlando, Florida, United States

🇺🇸

Texas Liver Institute, San Antonio, Texas, United States

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants

Phase 1
Terminated
Conditions
Ovarian Cancer
Solid Tumors
NSCLC
ESCC
Interventions
First Posted Date
2021-06-25
Last Posted Date
2024-12-11
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
16
Registration Number
NCT04939701
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

University of Miami, Miami, Florida, United States

🇺🇸

Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States

and more 3 locations

A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction

Phase 1
Terminated
Conditions
Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
Interventions
Drug: Placebo
First Posted Date
2021-04-22
Last Posted Date
2025-04-16
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
31
Registration Number
NCT04855201
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

Phase 1
Completed
Conditions
Advanced Malignancies
Advanced Cancer
Interventions
First Posted Date
2021-04-08
Last Posted Date
2024-11-13
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
24
Registration Number
NCT04837196
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

University of Iowa Hospitals, Iowa City, Iowa, United States

and more 1 locations

Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

Phase 1
Recruiting
Conditions
Prostate Cancer
Metastatic Castration Resistant Prostate Cancer
Metastatic Castration-sensitive Prostate Cancer
Interventions
First Posted Date
2021-01-28
Last Posted Date
2025-03-20
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
100
Registration Number
NCT04729114
Locations
🇺🇸

Los Angeles Cancer Network, Anaheim, California, United States

🇺🇸

Arizona Urology Specialists, Tucson, Arizona, United States

🇺🇸

Providence Medical Group Oncology Santa Rosa, Santa Rosa, California, United States

and more 21 locations

A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function

Phase 1
Completed
Conditions
Pharmacokinetics of ASP2215
Normal Renal Function
Renal Impaired
Gilteritinib
Interventions
First Posted Date
2021-01-07
Last Posted Date
2024-11-05
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
17
Registration Number
NCT04699877
Locations
🇺🇸

National Institute of Clinical Research, Garden Grove, California, United States

🇺🇸

Orange County Research Institute, Tustin, California, United States

🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath